Abstract
Radiation and chemotherapy are the main pillars of the current multimodal treatment concept for cancer patients. However, tumor recurrences and resistances still hamper treatment success regardless of advances in radiation beam application, particle radiotherapy, and optimized chemotherapeutics. To specifically intervene at key recurrence- and resistance-promoting molecular processes, the development of potent and specific molecular-targeted agents is demanded for an efficient, safe, and simultaneous integration into current standard of care regimens. Potential targets for such an approach are integrins conferring structural and biochemical communication between cells and their microenvironment. Integrin binding to extracellular matrix activates intracellular signaling for regulating essential cellular functions such as survival, proliferation, differentiation, adhesion, and cell motility. Tumor-associated characteristics such as invasion, metastasis, and radiochemoresistance also highly depend on integrin function. Owing to their dual functionality and their overexpression in the majority of human malignancies, integrins present ideal and accessible targets for cancer therapy. In the following chapter, the current knowledge on aspects of the tumor microenvironment, the molecular regulation of integrin-dependent radiochemoresistance and current approaches to integrin targeting are summarized.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
ClinicalTrials.gov. https://clinicaltrials.gov/.
References
Abdollahi A, Griggs DW, Zieher H et al (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270–6279. doi:10.1158/1078-0432.CCR-04-1223
Ahmed KM, Zhang H, Park CC (2013) NF-B regulates radioresistance mediated by 1-integrin in three-dimensional culture of breast cancer cells. Cancer Res 73:3737–3748. doi:10.1158/0008-5472.CAN-12-3537
Allison RR, Patel RM, McLawhorn RA (2014) Radiation oncology: physics advances that minimize morbidity. Future Oncol 10:2329–2344. doi:10.2217/fon.14.176
Arias JL (2011) Drug targeting strategies in cancer treatment: an overview. Mini-Rev Med Chem 11:1–17. doi:10.2174/138955711793564024
Barcellos-Hoff MH, Cordes N (2009) Resistance to radio- and chemotherapy and the tumour microenvironment. Int J Radiat Biol 85:920–922. doi:10.3109/09553000903274043
Barkan D, Chambers AF (2011) β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 17:7219–7223. doi:10.1158/1078-0432.CCR-11-0642
Barker HE, Paget JTE, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409–425. doi:10.1038/nrc3958
Bell-McGuinn KM, Matthews CM, Ho SN et al (2011) A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273–279. doi:10.1016/j.ygyno.2010.12.362
Bello L, Francolini M, Marthyn P, et al. (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49:380–839; discussion 390
Bradbury CM, Markovina S, Wei SJ et al (2001) Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-κB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Indomethacin-induced Radiosensitization and Inhibition of Ionizing via a Mechanism Involvi, pp 7689–7696
Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571
Butcher DT, Alliston T, Weaver VM (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9:108–122. doi:10.1038/nrc2544
Calderwood DA (2004) Integrin activation. J Cell Sci 117:657–666. doi:10.1242/jcs.01014
Carbonell WS, DeLay M, Jahangiri A et al (2013) β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 73:3145–3154. doi:10.1158/0008-5472.CAN-13-0011
Chen F, Zhuang X, Lin L et al (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13:45. doi:10.1186/s12916-015-0278-7
Cianfrocca ME, Kimmel KA, Gallo J et al (2006) Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 94:1621–1626. doi:10.1038/sj.bjc.6603171
Clark AG, Vignjevic DM (2015) Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol 36:13–22. doi:10.1016/j.ceb.2015.06.004
Coles A (2015) Newer therapies for multiple sclerosis. Ann Indian Acad Neurol 18:S30–S34. doi:10.4103/0972-2327.164824
Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2:689–700. doi:10.1038/nchembio840
Cordes N, Meineke V (2003) Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther Onkol 179:337–344. doi:10.1007/s00066-003-1074-4
Cordes N, Park CC (2007) B 1 Integrin as a molecular therapeutic target. Int J Radiat Biol 83:753–760. doi:10.1080/09553000701639694
Cordes N, Blaese MA, Meineke V, Van Beuningen D (2002) Ionizing radiation induces up-regulation of functional b1-integrin in human lung tumour cell lines in vitro. Int J Radiat Biol 78:347–357. doi:10.1080/0955300011011734
Cordes N, Hansmeier B, Beinke C et al (2003) Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer 89:2122–2132. doi:10.1038/sj.bjc.6601429
Damiano JS, Cress AE, Hazlehurst LA et al (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658–1667
Damiano JS, Hazlehurst LA, Dalton WS (2001) Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15:1232–1239
Danen EHJ (2005) Integrins: regulators of tissue function and cancer progression. Curr Pharm Des 11:881–891
Delbaldo C, Raymond E, Vera K et al (2008) Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 26:35–43. doi:10.1007/s10637-007-9077-0
Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22. doi:10.1038/nrc2748
Dickreuter E, Eke I, Krause M et al (2015) Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene. doi:10.1038/onc.2015.212
Ducassou A, Uro-Coste E, Verrelle P et al (2013) αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. Eur J Cancer 49:2161–2169. doi:10.1016/j.ejca.2013.02.033
Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18:884–901. doi:10.1016/j.devcel.2010.05.012
Eke I, Cordes N (2011) Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother Oncol 99:279–286. doi:10.1016/j.radonc.2011.06.006
Eke I, Cordes N (2015) Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol 31C:65–75. doi:10.1016/j.semcancer.2014.07.009
Eke I, Koch U, Hehlgans S et al (2010) PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest 120:2516–2527. doi:10.1172/JCI41078
Eke I, Storch K, Kästner I et al (2012a) Three-dimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation in vitro. Int J Radiat Oncol Biol Phys 84:e515–e523. doi:10.1016/j.ijrobp.2012.06.012
Eke I, Deuse Y, Hehlgans S et al (2012b) beta(1)Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 122:1529–1540. doi:10.1172/jci61350
Eke I, Dickreuter E, Cordes N (2012c) Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by beta1 integrin inhibition. Radiother Oncol 104:235–242. doi:10.1016/j.radonc.2012.05.009
Eke I, Schneider L, Förster C et al (2013) EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res 73:297–306. doi:10.1158/0008-5472.CAN-12-2021
Eke I, Zscheppang K, Dickreuter E et al (2015) Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer. J Natl Cancer Inst. doi:10.1093/jnci/dju419
Eliceiri BP, Cheresh DA (2000) Role of alpha v integrins during angiogenesis. Cancer J 6(Suppl 3):S245–S249
Eriksen JG, Steiniche T, Søgaard H, Overgaard J (2004) Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. Apmis 112:560–568. doi:10.1111/j.1600-0463.2004.apm1120902.x
Estilo CL, O-charoenrat P, Talbot S et al (2009) Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9:11. doi:10.1186/1471-2407-9-11
Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123:4195–4200. doi:10.1242/jcs.023820
Fujii T, Koshikawa K, Nomoto S et al (2004) Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol 41:104–111. doi:10.1016/j.jhep.2004.03.029
Fujita S, Watanabe M, Kubota T, et al. (1995) Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett 91:145–149. doi:030438359503735F [pii]
Gandellini P, Andriani F, Merlino G et al (2015) Complexity in the tumour microenvironment: cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. Semin Cancer Biol 35:96–106. doi:10.1016/j.semcancer.2015.08.008
Geiger B, Yamada KM (2011) Molecular architecture and function of matrix adhesions. Cold Spring Harb Perspect Biol 3:1–21. doi:10.1101/cshperspect.a005033
Geiger T, Zaidel-Bar R (2012) Opening the floodgates: proteomics and the integrin adhesome. Curr Opin Cell Biol 24:562–568. doi:10.1016/j.ceb.2012.05.004
Geiger B, Spatz JP, Bershadsky AD (2009) Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 10:21–33. doi:10.1038/nrm2593
Gensicke H, Leppert D, Yaldizli Ö et al (2012) Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 26:11–37. doi:10.2165/11596920-000000000-00000
Gingras MC, Roussel E, Bruner JM et al (1995) Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 57:143–153
Gladson CL, Cheresh DA (1991) Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 88:1924–1932. doi:10.1172/JCI115516
Golubovskaya VM, Huang G, Ho B et al (2013) Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 12:162–172. doi:10.1158/1535-7163.MCT-12-0701
Goodman SL, Picard M (2012) Integrins as therapeutic targets. Trends Pharmacol Sci 33:405–412. doi:10.1016/j.tips.2012.04.002
Gui GP, Wells CA, Yeomans P et al (1996) Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. Eur J Surg Oncol 22:254–258
Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816–826. doi:10.1038/nrm1490
Gutheil JC (2000) Novel immunologic and biologic therapies for breast cancer. Curr Oncol Rep 2:582–586
Hall PA, Coates P, Lemoine NR, Horton MA (1991) Characterization of integrin chains in normal and neoplastic human pancreas. J Pathol 165:33–41. doi:10.1002/path.1711650107
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
Harburger DS, Calderwood DA (2009) Integrin signalling at a glance. J Cell Sci 122:1472. doi:10.1242/jcs.052910
Hazlehurst LA, Damiano JS, Buyuksal I et al (2000) Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19:4319–4327. doi:10.1038/sj.onc.1203782
Hazlehurst LA, Argilagos RF, Emmons M et al (2006) Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res 66:2338–2345. doi:10.1158/0008-5472.CAN-05-3256
Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163–180. doi:10.1016/j.bbcan.2006.09.001
Hehlgans S, Eke I, Deuse Y, Cordes N (2008) Integrin-linked kinase: dispensable for radiation survival of three-dimensionally cultured fibroblasts. Radiother Oncol 86:329–335. doi:10.1016/j.radonc.2007.09.007
Hehlgans S, Lange I, Eke I, Cordes N (2009) 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother Oncol 92:371–378. doi:10.1016/j.radonc.2009.08.001
Hehlgans S, Eke I, Cordes N (2012) Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. Int J Radiat Oncol Biol Phys 83:e669–e676. doi:10.1016/j.ijrobp.2012.01.065
Heng DYC, Kollmannsberger C, Chi KN (2010) Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol 2:39–49. doi:10.1177/1758834009352498
Hersey P, Sosman J, O’Day S et al (2010) A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or − dacarbazine in patients with stage IV metastatic melanoma. Cancer 116:1526–1534. doi:10.1002/cncr.24821
Higgins GS, O’Cathail SM, Muschel RJ, McKenna WG (2015) Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treat Rev 41:105–113. doi:10.1016/j.ctrv.2014.12.012
Hochwald SN, Nyberg C, Zheng M et al (2009) A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 8:2435–2443
Horsley W, Nayar V, Auddy G (2015) Natalizumab use in multiple sclerosis: a real world evidence (Rwe) analysis of its impact on Nhs resources in England. Value Health 18:A764. doi:10.1016/j.jval.2015.09.2506
Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119:3901–3903. doi:10.1242/jcs.03098
Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673–687. doi:10.1016/S0092-8674(02)00971-6
Infante JR, Camidge DR, Mileshkin LR et al (2012) Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 30:1527–1533. doi:10.1200/JCO.2011.38.9346
Iwamoto DV, Calderwood DA (2015) Regulation of integrin-mediated adhesions. Curr Opin Cell Biol 36:41–47. doi:10.1016/j.ceb.2015.06.009
Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31:2205–2218. doi:10.1200/JCO.2012.46.3653
Janes SM, Watt FM (2006) New roles for integrins in squamous-cell carcinoma. Nat Rev Cancer 6:175–183. doi:10.1038/nrc1817
Jones J, Sugiyama M, Watt FM, Speight PM (1993) Integrin expression in normal, hyperplastic, dysplastic, and malignant oral epithelium. J Pathol 169:235–243. doi:10.1002/path.1711690210
Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501:346–354. doi:10.1038/nature12626
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401. doi:10.1038/nrc1877
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67. doi:10.1016/j.cell.2010.03.015
Klemm F, Joyce JA (2014) Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 25:198–213. doi:10.1016/j.tcb.2014.11.006
Koretz K, Schlag P, Boumsell L, Möller P (1991) Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 138:741–750
Koukoulis GK, Virtanen I, Korhonen M et al (1991) Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 139:787–799
Kumar S, Weaver VM (2009) Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 28:113–127. doi:10.1007/s10555-008-9173-4
Kurokawa A, Nagata M, Kitamura N et al (2008) Diagnostic value of integrin alpha3, beta4, and beta5 gene expression levels for the clinical outcome of tongue squamous cell carcinoma. Cancer 112:1272–1281. doi:10.1002/cncr.23295
Lark AL, Livasy CA, Dressler L et al (2005) High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 18:1289–1294. doi:10.1038/modpathol.3800424
Legate KR, Montañez E, Kudlacek O, Füssler R (2006) ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 7:20–31. doi:10.1038/nrm1789
Legate KR, Wickström S a, Fässler R et al (2009) Genetic and cell biological analysis of integrin outside-in signaling Genetic and cell biological analysis of integrin outside-in signaling. 23:397–418. doi:10.1101/gad.1758709
Levental KR, Yu H, Kass L et al (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891–906. doi:10.1016/j.cell.2009.10.027
Liu W, Bloom DA, Cance WG et al (2008) FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29:1096–1107. doi:10.1093/carcin/bgn026
Maurer GD, Tritschler I, Adams B et al (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 11:747–756. doi:10.1215/15228517-2009-012
McNeel DG (2005) Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemother Biol Response Modif 22:247–261
Meads MB, Gatenby RA, Dalton WS (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9:665–674. doi:10.1038/nrc2714
Meineke V, Gilbertz K-P, Schilperoort K et al (2002) Ionizing radiation modulates cell surface integrin expression and adhesion of COLO-320 cells to collagen and fibronectin in vitro. Strahlentherapie und Onkol 178:709–714. doi:10.1007/s00066-002-0993-9
Micke P, Ostman A (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:1217–1233. doi:10.1517/14728222.9.6.1217
Mikkelsen T, Brodie C, Finniss S et al (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124:2719–2727. doi:10.1002/ijc.24240
Miyazaki T, Kato H, Nakajima M et al (2003) FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 89:140–145. doi:10.1038/sj.bjc.6601050
Monferran S, Skuli N, Delmas C et al (2008) Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer 123:357–364. doi:10.1002/ijc.23498
Morse EM, Brahme NN, Calderwood DA (2014) Integrin cytoplasmic tail interactions. Biochemistry 53:810–820. doi:10.1021/bi401596q
Nagata M, Noman AA, Suzuki K et al (2013) ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma. BMC Cancer 13:410. doi:10.1186/1471-2407-13-410
Nakasone ES, Askautrud HA, Kees T et al (2012) Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21:488–503. doi:10.1016/j.ccr.2012.02.017
Nam J-M, Onodera Y, Bissell MJ, Park CC (2010) Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 70:5238–5248. doi:10.1158/0008-5472.CAN-09-2319
Niyazi M, Maihoefer C, Krause M et al (2011) Radiotherapy and “new” drugs-new side effects? Radiat Oncol 6:177. doi:10.1186/1748-717X-6-177
O’Day S, Pavlick A, Loquai C et al (2011) A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105:346–352. doi:10.1038/bjc.2011.183
Oliveira-Ferrer L, Hauschild J, Fiedler W et al (2008) Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27:86. doi:10.1186/1756-9966-27-86
Park CC, Henshall-Powell RL, Erickson AC et al (2003) Ionizing radiation induces heritable disruption of epithelial cell interactions. Proc Natl Acad Sci USA 100:10728–10733. doi:10.1073/pnas.1832185100
Park CC, Zhang H, Pallavicini M et al (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535. doi:10.1158/0008-5472.CAN-05-3071
Park CC, Zhang HJ, Yao ES et al (2008) Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 68:4398–4405. doi:10.1158/0008-5472.CAN-07-6390
Paulsson J, Micke P (2014) Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol 25:61–68. doi:10.1016/j.semcancer.2014.02.006
Paulus W, Baur I, Schuppan D, Roggendorf W (1993) Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 143:154–163
Peng C-H, Liao C-T, Peng S-C et al (2011) A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS ONE 6:e23452. doi:10.1371/journal.pone.0023452
Plodinec M, Loparic M, Monnier CA et al (2012) The nanomechanical signature of breast cancer. Nat Nanotechnol 7:757–765. doi:10.1038/nnano.2012.167
Polte TR, Hanks SK (1995) Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Proc Natl Acad Sci USA 92:10678–10682
Previtali S, Quattrini A, Nemni R et al (1996) Alpha6 beta4 and alpha6 beta1 integrins in astrocytomas and other CNS tumors. J Neuropathol Exp Neurol 55:456–465
Qin J, Wu C (2012) ILK: a pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr Opin Cell Biol 24:607–613. doi:10.1016/j.ceb.2012.06.003
Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617. doi:10.1200/JCO.2008.16.7510
Ricart AD, Tolcher AW, Liu G et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 14:7924–7929. doi:10.1158/1078-0432.CCR-08-0378
Rieken S, Habermehl D, Mohr A et al (2011) Targeting ανβ3 and ανβ5 inhibits photon-induced hypermigration of malignant glioma cells. Radiat Oncol 6:132. doi:10.1186/1748-717X-6-132
Ritchie CK, Giordano A, Khalili K (2000) Integrin involvement in glioblastoma multiforme: possible regulation by NF-kappaB. J Cell Physiol 184:214–221. doi:10.1002/1097-4652(200008)184:2<214:AID-JCP9>3.0.CO;2-Z
Roberts WG, Ung E, Whalen P et al (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935–1944. doi:10.1158/0008-5472.CAN-07-5155
Rønnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76:69–125
Rossow L, Eke I, Dickreuter E, Cordes N (2015) Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures. Oncol Rep 34:469–476
Salzler GG, Graham A, Connolly PH et al (2015) Safety and effectiveness of adjunctive intra-arterial abciximab in the management of acute limb ischemia. Ann Vasc Surg. doi:10.1016/j.avsg.2015.09.004
Sanchez-Lopez E, Flashner-Abramson E, Shalapour S et al (2015) Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene. doi:10.1038/onc.2015.326
Sandfort V, Koch U, Cordes N (2007) Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol 83:727–732. doi:10.1080/09553000701694335
Sandfort V, Eke I, Cordes N (2010) The role of the focal adhesion protein PINCH1 for the radiosensitivity of adhesion and suspension cell cultures. PLoS ONE. doi:10.1371/journal.pone.0013056
Schnell O, Krebs B, Wagner E et al (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18:378–386. doi:10.1111/j.1750-3639.2008.00137.x
Searle EJ, Illidge TM, Stratford IJ (2014) Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. Clin Oncol 26:266–276. doi:10.1016/j.clon.2014.02.006
Shi X, Meng X, Sun X et al (2014) PET/CT imaging-guided dose painting in radiation therapy. Cancer Lett 355:169–175. doi:10.1016/j.canlet.2014.07.042
Shimoyama S, Gansauge F, Gansauge S et al (1995) Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas. Int J Pancreatol 18:227–234
Shirakihara T, Kawasaki T, Fukagawa A et al (2013) Identification of integrin α3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes. Cancer Sci 104:1189–1197. doi:10.1111/cas.12220
Shishido S, Bönig H, Kim Y-M (2014) Role of integrin alpha4 in drug resistance of leukemia. Front Oncol 4:1–10. doi:10.3389/fonc.2014.00099
Stallmach A, von Lampe B, Matthes H et al (1992) Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut 33:342–346. doi:10.1136/gut.33.3.342
Steglich A, Vehlow A, Eke I, Cordes N (2015) α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells. Cancer Lett 357:542–548. doi:10.1016/j.canlet.2014.12.009
Storch K, Cordes N (2012) Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy. Chemother Res Pract 2012:319287. doi:10.1155/2012/319287
Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108. doi:10.1016/S1470-2045(14)70379-1
Tavora B, Reynolds LE, Batista S et al (2014) Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 514:112–116. doi:10.1038/nature13541
Thundimadathil J (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:967347. doi:10.1155/2012/967347
Tilghman RW, Parsons JT (2008) Focal adhesion kinase as a regulator of cell tension in the progression of cancer. Semin Cancer Biol 18:45–52. doi:10.1016/j.semcancer.2007.08.002
Vehlow A, Cordes N (2013) Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta—Rev Cancer 1836:236–244. doi:10.1016/j.bbcan.2013.07.001
Vogetseder A, Thies S, Ingold B et al (2013) αv-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer 133:2362–2371. doi:10.1002/ijc.28267
Wei SC, Yang J (2015) Forcing through tumor metastasis : the interplay between tissue rigidity and epithelial—mesenchymal transition. Trends Cell Biol xx:1–10. doi:10.1016/j.tcb.2015.09.009
Weis SM, Cheresh DA (2011) αv integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 1:1–14. doi:10.1101/cshperspect.a006478
Wick W, Wick A, Schulz B et al (2002) Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62:1915–1919
Wickström SA, Lange A, Hess MW et al (2010) Integrin-linked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev Cell 19:574–588. doi:10.1016/j.devcel.2010.09.007
Wild-bode C, Weller M, Rimner A et al (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells : implications for radiotherapy of human glioblastoma sublethal irradiation promotes migration and invasiveness of glioma cells : implications for radiotherapy of human glioblastoma. Cancer Res 61:2744–2750
Yamada KM, Even-Ram S (2002) Integrin regulation of growth factor receptors. Nat Cell Biol 4:E75–E76. doi:10.1038/ncb0402-e75
Zaidel-Bar R, Itzkovitz S, Ma’ayan A et al (2007) Functional atlas of the integrin adhesome. Nat Cell Biol 9:858–867. doi:10.1038/ncb0807-858
Zhou B, Gibson-Corley KN, Herndon ME et al (2014) Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol Cancer Res 12:143–154. doi:10.1158/1541-7786.mcr-13-0184
Zutter MM, Krigman HR, Santoro SA (1993) Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 142:1439–1448
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Vehlow, A., Storch, K., Matzke, D., Cordes, N. (2016). Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology. In: Baumann, M., Krause, M., Cordes, N. (eds) Molecular Radio-Oncology. Recent Results in Cancer Research, vol 198. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49651-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-662-49651-0_4
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49649-7
Online ISBN: 978-3-662-49651-0
eBook Packages: MedicineMedicine (R0)